Good starting point, but toxic culture and no growth. - Associate Scientist II Catalent Pharma Employee Review

2.0
Apr 15, 2026
Recommend
CEO approval
Business Outlook

Pros

It is a good starting point in the industry.

Cons

It is a good introduction into the industry, but it's not good for a long-term career. Get your foot in the door and then leave as soon as you build up some experience because the pay here is lower than industry standard so the best way to get a raise is to go somewhere else. There is little room for advancement. You will be hired for a specific role and pretty much forced to stay there because they don't want to hire enough people. Your workload will be too high to be able to learn and perform other tasks. The culture is toxic, consisting of insincere positivity and platitudes. They prefer the appearance of harmony by covering up and silencing concerns over addressing concerns to actually achieve harmony.

Explore other reviews about Catalent Pharma

5.0
May 26, 2026
Recommend
CEO approval
Business Outlook

Pros

The team is incredibly welcoming, knowledgeable, and supportive, which has made it easy to learn and feel comfortable asking questions. There is a strong focus on training and collaboration, helping me feel safe, well prepared, and confident in my role. I also appreciate the benefits, which support a good work-life balance.

Cons

One area for improvement is the flexibility for new employees regarding remote work hours.

1.0
Feb 26, 2026
Recommend
CEO approval
Business Outlook

Pros

-Colleagues in labs and manufacturing sites are knowledgeable, dedicated, and supportive of one another. - Compensation and benefits remain competitive within the contract development and manufacturing industry. - Employees gain meaningful hands-on experience with advanced gene therapy and biologics projects. - Certain facilities feature modern equipment that supports complex production requirements. - Occasional team events and basic perks help build occasional positive moments in the workplace.

Cons

- The executive team consists primarily of finance professionals with limited direct experience in biopharmaceutical operations and quality systems. - Substantial debt accumulation and strategic divestitures occurred without sufficient investment in core manufacturing infrastructure or process improvements. - High employee turnover and repeated layoffs have led to increased workloads, reduced staffing levels, and declining team morale. - Persistent gaps in training, documentation, and maintenance contribute to quality deviations and regulatory compliance difficulties. - Communication between departments is often limited, resulting in unrealistic timelines and frequent project delays. - The company faced significant financial pressures approaching instability prior to the private acquisition. - Professional development opportunities are minimal, recognition is inconsistent, and work-life balance remains challenging for most roles

4
See reviews by: Helpful|Rating|Date|All